Logo image of CGC

CANOPY GROWTH CORP (CGC) Stock Fundamental Analysis

NASDAQ:CGC - Nasdaq - CA1380357048 - Common Stock - Currency: USD

1.14  +0.03 (+2.7%)

After market: 1.14 0 (0%)

Fundamental Rating

2

CGC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CGC have multiple concerns. CGC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CGC has reported negative net income.
CGC had a negative operating cash flow in the past year.
In the past 5 years CGC always reported negative net income.
CGC had a negative operating cash flow in each of the past 5 years.
CGC Yearly Net Income VS EBIT VS OCF VS FCFCGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1B -2B -3B

1.2 Ratios

With a Return On Assets value of -65.18%, CGC is not doing good in the industry: 66.49% of the companies in the same industry are doing better.
The Return On Equity of CGC (-122.76%) is worse than 62.89% of its industry peers.
Industry RankSector Rank
ROA -65.18%
ROE -122.76%
ROIC N/A
ROA(3y)-83.37%
ROA(5y)-56.25%
ROE(3y)-219.63%
ROE(5y)-143.17%
ROIC(3y)N/A
ROIC(5y)N/A
CGC Yearly ROA, ROE, ROICCGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

With a Gross Margin value of 30.30%, CGC perfoms like the industry average, outperforming 55.67% of the companies in the same industry.
CGC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGC Yearly Profit, Operating, Gross MarginsCGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

3

2. Health

2.1 Basic Checks

CGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CGC has been increased compared to 1 year ago.
The number of shares outstanding for CGC has been reduced compared to 5 years ago.
The debt/assets ratio for CGC has been reduced compared to a year ago.
CGC Yearly Shares OutstandingCGC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
CGC Yearly Total Debt VS Total AssetsCGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

CGC has an Altman-Z score of -12.70. This is a bad value and indicates that CGC is not financially healthy and even has some risk of bankruptcy.
CGC has a worse Altman-Z score (-12.70) than 75.26% of its industry peers.
CGC has a Debt/Equity ratio of 0.64. This is a neutral value indicating CGC is somewhat dependend on debt financing.
CGC has a worse Debt to Equity ratio (0.64) than 64.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Altman-Z -12.7
ROIC/WACCN/A
WACC12.11%
CGC Yearly LT Debt VS Equity VS FCFCGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B

2.3 Liquidity

A Current Ratio of 3.12 indicates that CGC has no problem at all paying its short term obligations.
CGC has a Current ratio (3.12) which is comparable to the rest of the industry.
CGC has a Quick Ratio of 2.10. This indicates that CGC is financially healthy and has no problem in meeting its short term obligations.
CGC's Quick ratio of 2.10 is in line compared to the rest of the industry. CGC outperforms 45.36% of its industry peers.
Industry RankSector Rank
Current Ratio 3.12
Quick Ratio 2.1
CGC Yearly Current Assets VS Current LiabilitesCGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.57% over the past year.
The Revenue has decreased by -9.49% in the past year.
CGC shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.57% yearly.
EPS 1Y (TTM)34.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.72%
Revenue 1Y (TTM)-9.49%
Revenue growth 3Y-19.22%
Revenue growth 5Y-7.57%
Sales Q2Q%-6.22%

3.2 Future

The Earnings Per Share is expected to grow by 15.29% on average over the next years. This is quite good.
The Revenue is expected to grow by 4.64% on average over the next years.
EPS Next Y89.5%
EPS Next 2Y38.49%
EPS Next 3Y23.41%
EPS Next 5Y15.29%
Revenue Next Year7.13%
Revenue Next 2Y6.99%
Revenue Next 3Y5.97%
Revenue Next 5Y4.64%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CGC Yearly Revenue VS EstimatesCGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
CGC Yearly EPS VS EstimatesCGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGC Price Earnings VS Forward Price EarningsCGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGC Per share dataCGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as CGC's earnings are expected to grow with 23.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.49%
EPS Next 3Y23.41%

More info and screens

0

5. Dividend

5.1 Amount

CGC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANOPY GROWTH CORP

NASDAQ:CGC (7/25/2025, 8:00:00 PM)

After market: 1.14 0 (0%)

1.14

+0.03 (+2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-30 2025-05-30/bmo
Earnings (Next)08-08 2025-08-08/bmo
Inst Owners8.19%
Inst Owner Change1.21%
Ins Owners0.94%
Ins Owner Change52.35%
Market Cap263.81M
Analysts46.67
Price Target2.19 (92.11%)
Short Float %9.9%
Short Ratio2.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-153.89%
Min EPS beat(2)-206.63%
Max EPS beat(2)-101.15%
EPS beat(4)0
Avg EPS beat(4)-194.79%
Min EPS beat(4)-240.27%
Max EPS beat(4)-101.15%
EPS beat(8)1
Avg EPS beat(8)-180.52%
EPS beat(12)1
Avg EPS beat(12)-197.59%
EPS beat(16)4
Avg EPS beat(16)-139.13%
Revenue beat(2)2
Avg Revenue beat(2)6.85%
Min Revenue beat(2)6.06%
Max Revenue beat(2)7.65%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-8.11%
Max Revenue beat(4)7.65%
Revenue beat(8)5
Avg Revenue beat(8)4.78%
Revenue beat(12)6
Avg Revenue beat(12)0.48%
Revenue beat(16)7
Avg Revenue beat(16)-2.12%
PT rev (1m)6.73%
PT rev (3m)-19.61%
EPS NQ rev (1m)-25.7%
EPS NQ rev (3m)-25.7%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-9.49%
Revenue NQ rev (3m)-9.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.34
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-4.14
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0.85
BVpS1.54
TBVpS1.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.18%
ROE -122.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.3%
FCFM N/A
ROA(3y)-83.37%
ROA(5y)-56.25%
ROE(3y)-219.63%
ROE(5y)-143.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.16%
Cap/Sales 4.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.12
Quick Ratio 2.1
Altman-Z -12.7
F-Score5
WACC12.11%
ROIC/WACCN/A
Cap/Depr(3y)15.39%
Cap/Depr(5y)45.04%
Cap/Sales(3y)2.72%
Cap/Sales(5y)9.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.72%
EPS Next Y89.5%
EPS Next 2Y38.49%
EPS Next 3Y23.41%
EPS Next 5Y15.29%
Revenue 1Y (TTM)-9.49%
Revenue growth 3Y-19.22%
Revenue growth 5Y-7.57%
Sales Q2Q%-6.22%
Revenue Next Year7.13%
Revenue Next 2Y6.99%
Revenue Next 3Y5.97%
Revenue Next 5Y4.64%
EBIT growth 1Y48.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year103.26%
EBIT Next 3Y30.78%
EBIT Next 5Y20.32%
FCF growth 1Y38.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.21%
OCF growth 3YN/A
OCF growth 5YN/A